Compare Davita Inc (DVA) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares MSCI India ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while iShares MSCI India ETF trades at $46.11 (market cap $5.81B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and iShares MSCI India ETF for 57 Days on average.
| DVA | INDA | |
|---|---|---|
Market Cap | $11.29B | $5.81B |
Volume | 582,204 | 5,590,429 |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $55.29 |
52-Week Low | $103.87 | $45.42 |
Typical Hold Time | 113 Days | 57 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
INDA is trading at $46.12, down 1.31% with a bearish technical signal across moving averages and oscillators. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and pharmaceutical sector export issues. Technical indicators show oversold conditions with RSI readings below 30, while support and resistance cluster around $46.
The outlook remains cautious given India's infrastructure constraints and global trade tensions. Investment opportunity exists for long-term exposure to India's growth story, but risks include energy security concerns, weather-related agricultural impacts, and IT sector weakness. Current technical oversold conditions may present entry points for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
